FDA Panel Pans Bladder Cancer Therapy (CME/CE)

(MedPage Today) -- Too few patients, modest benefit cited in negative vote
Source: MedPage Today Public Health - Category: American Health Source Type: news

Related Links:

Abstract As a new group of important effector molecules involved in multiple cancers, long noncoding RNAs (lncRNAs) have attracted much attention recently. Especially, evidences have indicated lncRNAs might be promising biomarkers and targets for cancer therapy. LINC00641 is a novel lncRNA, whose function remains totally unclear. The aim of our study was to determine the functions of LINC00641 in bladder cancer. We found that LINC00641 expression was significantly down-regulated in bladder cancer tissues. Down-regulation of LINC00641 in patients with bladder cancer predicts poor prognosis. Gain-of-function assays ...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
In this study, the potential for SWNHs to serve as nanotheranostic vehicles is demonstrated through simultaneous delivery of the chemotherapeutic cisplatin from SWNH cone interiors and imaging of the nanoparticle transport to tumor cells using conjugated quantum dots (QDs). Following the formation of cisplatin-modified SWNH-QD (SWNH-QD + cis) hybrids, their characterization by scanning and transmission electron microscopy (STEM, TEM), energy dispersive spectroscopy (EDS), and dynamic light scattering (DLS) were performed to characterize the composite nanoparticles. Drug release profiles and 50% inhibitory concent...
Source: Carbon - Category: Materials Science Source Type: research
With the exponentially increasing costs of cancer therapies, there has been an increased emphasis on chemoprevention of disease. Emerging evidence demonstrates a potential role for the androgen axis in the development and progression of bladder cancer but the relationship has not been fully characterized.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Editorial Source Type: research
In this study, the potential for SWNHs to serve as nanotheranostic vehicles is demonstrated through simultaneous delivery of the chemotherapeutic cisplatin from SWNH cone interiors and imaging of the nanoparticle transport to tumor cells using conjugated quantum dots (QDs). Following the formation of cisplatin-modified SWNH-QD (SWNH-QD + cis) hybrids, their characterization by scanning and transmission electron microscopy (STEM, TEM), energy dispersive spectroscopy (EDS), and dynamic light scattering (DLS) were performed to characterize the composite nanoparticles. Drug release profiles and 50% inhibitory concent...
Source: Carbon - Category: Materials Science Source Type: research
Conclusion: This study not only demonstrated the great potential of HSA-MnO2-Ce6 NPs for bladder cancer photodynamic ablation but also provided a new therapeutic strategy to overcoming tumor hypoxia.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
This study characterizes the exclusion of patients with chronic kidney disease (CKD) in randomized clinical trials of drug treatment for bladder, breast, colorectal, lung, and prostate cancer.
Source: JAMA - Category: General Medicine Source Type: research
Authors: Okura Y, Ishigaki S, Sakakibara S, Yumoto C, Hashitate M, Sekine C, Fujita T, Takayama T, Ozaki K, Sato N, Minamino T Abstract Aortic stenosis (AS) is a life-threatening comorbidity of cancer patients. Aortic valve replacement (AVR) should be considered for some cancer patients, but neither the characteristics nor prognosis under conservative therapy is well known.We searched our echocardiography log (years 2005-2014) for cancer patients with AS, and 92 patients (54% female) were included in the study. To compare the survival curves, 470 control patients without AS were selected from our cancer registry.Me...
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
(Ruhr-University Bochum) Researchers from Bochum have detected an olfactory receptor in the human bladder that might prove useful for bladder cancer therapy and diagnosis. Using cell culture studies, the team headed by Professor Dr. Hanns Hatt and Dr. Lea Weber demonstrated that the receptor occurs more frequently in bladder cancer tissue than in healthy bladder tissue. Accordingly, significant higher amounts of the receptor could be found in the urine samples of patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
The primary treatment for high-grade non-muscle invasive bladder cancer (NMIBC) is based on surgery by transurethral resection of bladder tumor (TURBT), followed by intravesical immunotherapy with Bacillus Calmette-Guerin (BCG) to prevent recurrence and to reduce the tumor progression. However, BCG therapy shows several undesirable effects. The current treatment on NMIBC is doxorubicin (DOX), but with high toxicity. Our nanotechnology strategy was done through scaffolds for the NMIBC treatment: graphene oxide (GO) and a nanostructured lipid carrier (NLC). A GO hybrid for administration of DOX and small interfering RNA (siR...
Source: Journal of the Brazilian Chemical Society - Category: Chemistry Source Type: research
ConclusionConcomitant TURBT and TURP appear to be oncologically safe procedures in terms of total and prostatic urethra recurrence, and improve QL in men with BC who require surgery for symptomatic BPH.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
More News: American Health | Bladder Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Health | International Medicine & Public Health